I'll note that having the Vafseo TDAPA in place along with AURYXIA's upcoming TDAPA for the phosphate binder class they are both additional levers that we can pull as we pursue additional ...

Piper Sandler analyst Allison Bratzel maintained a Buy rating on Akebia Therapeutics (AKBA – Research Report) today and set a price ...

After hours: November 29 at 4:59 PM EST Loading Chart for AKBA ...

Investors should expect continued strength from Auryxia’s revenue. Not only does the company have contracts in place, but it also noted that providers are looking for bundles. The patent ...

Akebia已经获得了报销协议，并正在积极与医疗界接触，以支持Vafseo的优势。公司报告本季度净亏损2000万美元，这归因于Vafseo上市前活动支出增加以及现有产品AURYXIA收入下降。 要点 Akebia 2024年第三季度总收入为3740万美元，低于2023年第三季度的4200万美元。

After hours: 29 November at 4:59 pm GMT-5 ...

After hours: 27 November at 18:35 GMT-5 ...